CoChat
Sign Up
Cited by 636Antiplatelet Therapy and Cardiovascular DiseasesPeripheral Artery Disease ManagementCoronary Interventions and Diagnostics

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease

Open access
Hiatt, William R., Fowkes, F. Gerry R., Heizer, Gretchen, Berger, Jeffrey S., Baumgartner, Iris, Held, Peter, Katona, Brian G., Mahaffey, Kenneth W., Norgren, Lars, Jones, W. Schuyler, Blomster, Juuso, Millegård, Marcus, Reist, Craig, Patel, Manesh R.·2017·New England Journal of Medicine
DOI 10.1056/nejmoa1611688
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Peripheral artery disease is considered to be a manifestation of systemic atherosclerosis with associated adverse cardiovascular and limb events. Data from previous trials have suggested that patients receiving clopidogrel monotherapy had a lower risk of cardiovascular events than those receiving aspirin. We wanted to compare clopidogrel with ticagrelor, a potent antiplatelet agent, in patients with peripheral artery disease. METHODS: In this double-blind, event-driven trial, we randomly assigned 13,885 patients with symptomatic peripheral artery disease to receive monotherapy with ticagrelor (90 mg twice daily) or clopidogrel (75 mg once daily). Patients were eligible if they had an ankle-brachial index (ABI) of 0.80 or less or had undergone previous revascularization of the lower limbs. The primary efficacy end point was a composite of adjudicated cardiovascular death, myocardial infarction, or ischemic stroke. The primary safety end point was major bleeding. The median follow-up was 30 months. RESULTS: The median age of the patients was 66 years, and 72% were men; 43% were enrolled on the basis of the ABI and 57% on the basis of previous revascularization. The mean baseline ABI in all patients was 0.71, 76.6% of the patients had claudication, and 4.6% had critical limb ischemia. The primary efficacy end point occurred in 751 of 6930 patients (10.8%) receiving ticagrelor and in 740 of 6955 (10.6%) receiving clopidogrel (hazard ratio, 1.02; 95% confidence interval [CI], 0.92 to 1.13; P=0.65). In each group, acute limb ischemia occurred in 1.7% of the patients (hazard ratio, 1.03; 95% CI, 0.79 to 1.33; P=0.85) and major bleeding in 1.6% (hazard ratio, 1.10; 95% CI, 0.84 to 1.43; P=0.49). CONCLUSIONS: In patients with symptomatic peripheral artery disease, ticagrelor was not shown to be superior to clopidogrel for the reduction of cardiovascular events. Major bleeding occurred at similar rates among the patients in the two trial groups. (Funded by AstraZeneca; EUCLID ClinicalTrials.gov number, NCT01732822 .).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1611688

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

Sorted by citations

Items 401–500 of 633

Related

See all

Metadata

Authors
Hiatt, W. R., Fowkes, F. G. R., Heizer, G., Berger, J. S., Baumgartner, I., Held, P., Katona, B. G., Mahaffey, K. W., Norgren, L., Jones, W. S., Blomster, J., Millegård, M., Reist, C., & Patel, M. R.
Affiliations
University of Bern (CH)
ORCID
Venue
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Published
2017-01-05
Volume
376
Issue
1
Pages
32-40
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
DOI
10.1056/nejmoa1611688
OpenAlex
W2556414715
Cited by
636
References
14
Citations by year
2026: 26 · 2025: 42 · 2024: 57 · 2023: 59 · 2022: 60 · 2021: 85 · 2020: 75 · 2019: 80 · 2018: 87 · 2017: 60
FWCI
63.57
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Discovery Research Portal (University of Dundee) (publishedVersion, other-oa)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
  • Amgen
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • AstraZeneca
  • GlaxoSmithKline
  • Sanofi
  • Purdue University
  • Boston Scientific Corporation
  • Cook Medical
  • Purdue Pharma
  • MyoKardia
  • Mitsubishi Tanabe Pharma Corporation
  • St. Jude Medical
  • Abbott Vascular
  • Janssen Research and Development
  • Duke Clinical Research Institute
  • Daiichi Sankyo Europe
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
  • Health Sciences › Medicine › Surgery › Peripheral Artery Disease Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
Keywords
ticagrelor, clopidogrel, peripheral arterial disease, antiplatelet therapy, major bleeding, acute limb ischemia, cardiovascular events, ankle-brachial index, critical limb ischemia, claudication, lower extremity revascularization, cardiovascular mortality, ischemic stroke, myocardial infarction, P2Y12 inhibitors, aspirin, atherosclerosis
MeSH terms
Clopidogrel, Ticagrelor, Adenosine, Aged, Cardiovascular Diseases, Double-Blind Method, Female, Hemorrhage, Humans, Intermittent Claudication, Ischemia, Leg, Male, Middle Aged, Platelet Aggregation Inhibitors, Ticlopidine, Kaplan-Meier Estimate, Peripheral Arterial Disease, Purinergic P2Y Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review